-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On Latigo Biotherapeutics with Buy Rating, Announces Price Target of $50

Benzinga·09/01/2026 12:41:11
Listen to the news
Guggenheim analyst Yatin Suneja initiates coverage on Latigo Biotherapeutics (NASDAQ:LTGO) with a Buy rating and announces Price Target of $50.